bioAffinity reports positive preclinical data for siRNA therapy targeting squamous, basal skin cancer cells

• bioAffinity Technologies will present preclinical in vitro findings at the 2026 RNA Therapeutics (RNATx) Symposium.
• The study showed its proprietary siRNA approach selectively killed or slowed squamous and basal skin cancer cells while sparing healthy skin cells.
• The results support development of a topical treatment strategy for two high-incidence skin cancers where surgery can leave residual disease or recurrence risk.
• No human testing has been conducted, with no FDA IND filed for the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260622115344) on June 22, 2026, and is solely responsible for the information contained therein.